Hospital
Hardin Memorial Hospital
Hardin Memorial Hospital was paid $7.27M by Medicaid between Jan 2018 and Dec 2024, across 126 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoHARDIN MEMORIAL HOSPITAL
KENTON, OH 43326
KENTON, OH 43326
33aNPI1437181518assigned 07/07/2006
33bProvider typeCritical Access Hospital
28Total paid$7.27M
24GClaims165,936
24DCodes billed126
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#12 of 26
Median peer was paid$5.33M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BROWNING, MICHAEL controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,582 | $651K | |
| 2019 | 15,585 | $664K | |
| 2020 | 12,770 | $702K | |
| 2021 | 17,960 | $720K | |
| 2022 | 14,038 | $605K | |
| 2023 | 55,857 | $2.28M | |
| 2024incomplete | 33,144 | $1.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 14,995 | 13,407 | $1.78M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 7,713 | 6,660 | $977K |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 2,953 | 1,959 | $950K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 11% | 9,026 | 7,766 | $785K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.0% | 3,256 | 2,700 | $435K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.4% | 3,761 | 3,266 | $392K |
| 0240U | 3.4% | 1,861 | 1,471 | $250K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 3,266 | 789 | $219K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.9% | 763 | 612 | $213K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 708 | 499 | $186K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 594 | 468 | $152K |
| 80053 | Comprehensive metabolic panel | 1.4% | 8,993 | 7,318 | $100K |
114 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 637 | $90K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 762 | $88K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 322 | $73K |
| 97016 | <1% | 991 | $48K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,508 | $45K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 261 | $44K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,146 | $35K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 922 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,428 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,466 | $24K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 133 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,157 | $19K |
| 80061 | Lipid panel | <1% | 1,003 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,539 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 874 | $11K |
| G0378 | Hospital observation service, per hour | <1% | 257 | $11K |
| 73630 | <1% | 350 | $11K | |
| 84484 | <1% | 2,962 | $10K | |
| 82805 | <1% | 317 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 179 | $9K |
| 73130 | <1% | 371 | $9K | |
| 74018 | <1% | 217 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 672 | $9K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 43 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 671 | $8K |
| 73610 | <1% | 333 | $8K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $8K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 622 | $7K |
| J3490 | Unclassified drugs | <1% | 471 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,976 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,186 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,935 | $6K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 27 | $6K |
| 73030 | <1% | 172 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 119 | $5K |
| 72100 | <1% | 169 | $5K | |
| 81001 | <1% | 6,932 | $5K | |
| 73110 | <1% | 162 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 165 | $4K |
| 73560 | <1% | 162 | $4K | |
| 82728 | <1% | 242 | $4K | |
| 87077 | <1% | 246 | $4K | |
| 85610 | <1% | 1,416 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 31 | $3K |
| 97162 | <1% | 141 | $3K | |
| 85027 | <1% | 507 | $3K | |
| 82607 | <1% | 105 | $2K | |
| 97161 | <1% | 35 | $2K | |
| 84703 | <1% | 1,260 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 179 | $2K |
| 83880 | <1% | 837 | $2K | |
| 82565 | <1% | 2,319 | $2K | |
| 80051 | <1% | 2,234 | $2K | |
| 83735 | <1% | 376 | $2K | |
| 84702 | <1% | 89 | $1K | |
| 87186 | <1% | 198 | $1K | |
| 80076 | <1% | 1,228 | $1K | |
| 82248 | <1% | 587 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $1K |
| 83540 | <1% | 139 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,164 | $1K |
| 86140 | <1% | 105 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 745 | $1K |
| 84439 | <1% | 54 | $801.66 | |
| 73562 | <1% | 12 | $761.56 | |
| 73502 | <1% | 35 | $727.98 | |
| 83550 | <1% | 103 | $696.16 | |
| 83690 | <1% | 1,816 | $652.38 | |
| 84520 | <1% | 2,238 | $624.97 | |
| 85652 | <1% | 50 | $596.00 | |
| 82947 | <1% | 2,222 | $588.59 | |
| 82077 | <1% | 396 | $536.24 | |
| 76830 | Ultrasound, transvaginal | <1% | 15 | $530.51 |
| 83605 | <1% | 910 | $513.62 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 133 | $457.36 |
| 74022 | <1% | 20 | $456.34 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $427.60 |
| 82570 | <1% | 35 | $417.74 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 784 | $400.38 |
| 36416 | <1% | 615 | $344.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $213.83 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $213.83 |
| 85379 | <1% | 510 | $136.38 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,616 | $130.22 |
| 87040 | <1% | 177 | $115.25 | |
| 82150 | <1% | 30 | $114.98 | |
| 87081 | <1% | 134 | $76.93 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 69 | $73.17 |
| 80143 | <1% | 35 | $70.81 | |
| 87205 | <1% | 13 | $70.10 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,347 | $67.63 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 223 | $55.78 |
| 96376 | <1% | 278 | $40.03 | |
| 80179 | <1% | 33 | $35.40 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 290 | $29.38 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,245 | $27.57 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 257 | $16.72 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 43 | $12.75 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 21 | $9.47 |
| 85730 | <1% | 15 | $8.58 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 173 | $5.96 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 162 | $5.95 |
| J2704 | Injection, propofol, 10 mg | <1% | 338 | $5.81 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 66 | $5.28 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 77 | $0.35 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 55 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 108 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 17 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 31 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 35 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 71 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,196 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 17 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 49 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWNING, MICHAEL (CFO, OHIOHEALTH)
| Provider | Location | Paid |
|---|---|---|
| Ohiohealth Corporation | Columbus, OH | $214.99M |
| Ohiohealth Corporation | Columbus, OH | $76.95M |
| Ohiohealth Corporation | Columbus, OH | $72.29M |
| Ohiohealth Corporation | Columbus, OH | $44.08M |
| Medcentral Health System | Mansfield, OH | $36.92M |
| Marion General Hospital, INC. | Marion, OH | $36.47M |
| Sheltering Arms Hospital Foundation, INC. | Athens, OH | $26.88M |
| Ohiohealth Berger Hospital LLC | Circleville, OH | $16.38M |
| Ohiohealth Corporation | Dublin, OH | $11.81M |
| Grady Memorial Hospital | Delaware, OH | $9.51M |
| Medcentral Health System | Mansfield, OH | $3.13M |
| Madison Family Health Corporation | London, OH | $1.03M |
| Marion General Hospital, INC. | Marion, OH | $683K |
| Medcentral Health System | Mansfield, OH | $477K |
| Sheltering Arms Hospital Foundation | Athens, OH | $435K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.